PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management

Thrombosis and Hemostasis Management (THM) is the newest category of specialty residency training for pharmacists recognized by the American Society of Health-System Pharmacists (ASHP), the sole accrediting body for pharmacy residency programs in the United States. Created in 2022, this dynamic clinical specialty spans all aspects of the health care system, including ambulatory and acute care experiences, and provides focused training in emergency medicine, cardiology, critical care, hematology, and much more. Anticoagulation Forum is pleased to support the growth THM programs around the country as a key means of advancing safe and effective anticoagulant-related care and promoting Anticoagulation Stewardship.

Anticoagulation Forum TRAIN Pharmacy Grant: Thrombosis/Hemostasis Residency Award and Innovation Network


Grant Funding for PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management

This recently established 1-year residency, authorized by ASHP, will increase the number of expert clinicians equipped to effectively manage patients at risk for thrombosis and bleeding, and support the creation of anticoagulation stewardship programs nationwide.

Grant Award
The award payment offers each institution $120,000 over a 2-year period. The goal of this grant is to support the institution in developing the new program, as well as provide salary assistance for two consecutive residency years.

Application Dates
AC Forum will announce new funding opportunities in Fall 2024 to support residents beginning in July 2026.

Review Process and Notification
Institutions will be selected by an Anticoagulation Forum Review Committee based on their ability to train well-rounded residents, clinical and research expertise in relevant areas, and the program’s focus on thrombosis and hemostasis management. Reviewers with a conflict of interest will be recused from reviewing the specific application. Selected institutions will be notified of grant awards and will be required to sign a Grant Agreement with the Anticoagulation Forum.

Eligibility for AC Forum TRAIN Pharmacy Grant

Applicants must be US-based organizations with existing ASHP-accredited pharmacy residency programs and advanced pharmacy practices in the prevention and treatment of thrombosis and bleeding.

The Residency Program Director (RPD) must have either 1) completed a PGY2 residency in a related specialty area and have 3+ years of practice experience OR 2) have 5 years of practice experience in a relevant specialty area. The RPD should also be board certified in either Pharmacotherapy, Ambulatory Care, or Cardiology or have obtained recognition as a Certified Anticoagulation Care Provider from the National Certification Board for Anticoagulation Providers. The Director must also actively practice in a clinical area involving anticoagulation management.

Each awarded residency program will select the PGY2 resident via their own selection process, using their own criteria such as clinical excellence, academic potential, leadership ability, teaching skills, and demonstrated interest in thrombosis and hemostasis-related care. The AC Forum recommends that diversity, equity, and inclusion be prioritized as part of the selection process at each institution.

Grant Application Process

Sites will be asked to provide the following in the application:

  • Program contact information
  • List of current PGY2 pharmacy residencies
  • Candidate recruitment plan
  • Budget breakdown
  • Program description that includes:
    • Brief curriculum outline and learning experiences you intend to offer. Distinguish between required and elective experiences, and indicate whether each is a formal block or longitudinal.
    • The institution’s current service(s) in thrombosis and hemostasis management
    • The pharmacy department’s involvement in managing thrombosis and hemostasis
    • Potential preceptors to be involved in residency training (include a short bio of each faculty member). Please also identify a proposed residency program director.
    • Research opportunities for the resident
  • Letter of support from the Director of Pharmacy
  • Letter of support from a physician champion with a practice focus in thrombosis and hemostasis

Review Process and Notification

Institutions will be selected by an Anticoagulation Forum Review Committee based on their ability to train well-rounded residents, clinical and research expertise in relevant areas, and the program’s focus on thrombosis and hemostasis management. Reviewers with a conflict of interest will be recused from reviewing the specific application. Selected institutions will be notified of grant awards and will be required to sign a Grant Agreement with the Anticoagulation Forum.

Questions the Review Committee will consider include:

  • Does the program have faculty that can provide robust training?
  • What is the likelihood strong residents will apply/accept the program?
  • What types of research opportunities exist for/within the program?
  • How does the pharmacy department drive thrombosis and hemostasis clinical initiatives?
  • What is the likelihood the resident will have an impact in the field?
  • What is the likelihood of job placement after residency?

ASHP Accreditation Process and Timeline

Awarded sites will be required to pursue accreditation through ASHP. The residency accreditation process is independent from the TRAIN grant program.

Official resources for ASHP accreditation are available here.

PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management Learning Objectives

The PGY2 residency follows program competencies defined by ASHP. Please review them here: PGY2 Competency Areas.

TRAIN Pharmacy Seminar Series

Residents, along with their RPDs, will be expected to participate in a virtual seminar series moderated by faculty from each of the AC Forum PGY2 Residency sites. Seminars will focus on key subject matter topics within the thrombosis and hemostasis curriculum, as well as those related to career development. Residents will also have the opportunity to present complex cases to senior panelists.

RPDs and their faculty will work collaboratively to develop the content and syllabus for the seminar series, with support from the Anticoagulation Forum.

Financial Disclosure and Compliance

Institutions must be able to accept grant funding that may be subject to Sunshine Act reporting. The Anticoagulation Forum may be required to report information on the Residency award institution, Residency Program Director, resident, or other details of the program to AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc. to comply with the Sunshine Act.

Funding for the TRAIN Pharmacy Grant is provided by AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc.

Resources for securing administrative support for AC Stewardship Programs

The following ACF resources may be of value to organizations seeking to establish residency programs and expand Anticoagulation Stewardship initiatives.

Securing Administrative Leadership Support for Anticoagulation Stewardship Programs

Open access manuscript providing guidance on how to prioritize stewardship initiatives and prepare proposals to senior leadership.

Profiles in Progress

Evidence-based infographic profiling successes of anticoagulation stewardship programs around the country.

Evidence of Impact

Evidence-based infographic showing how anticoagulation stewardship initiatives have successfully closed gaps in the quality and safety of anticoagulation-related care

PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management


Current Thrombosis & Hemostasis Management Residency Sites (as of July 2023)

Prospective candidates are encouraged to explore the links to each site and any additional resources provided:

*Funded by Anticoagulation Forum’s TRAIN Grant

Let’s hear from the first-in-nation THM resident!
Kristi Schwietz, Brigham and Women’s Hospital


Inaugural PGY2 Residency in Thrombosis and Hemostasis Management Initiated at the Brigham and Women’s Hospital

The Brigham & Women’s Hospital, Boston Massachusetts launched the nation's first PGY2 Residency in Thrombosis and Hemostasis Management in July 2022. This novel specialty residency program was formally approved by the ASHP Council on Credentialing (COC) in April 2022. The necessary framework on goals, objectives and structure have been finalized and were posted in PharmAcademic in Fall 2022 for programs interested in accessing this information.

Program Need

Anticoagulants are the leading class of medications associated with emergency department visits for adverse events. The rapid expansion of approved anticoagulants, indications for their use, associated reversal strategies, and increasing overall prescribing makes safe and effective patient care increasingly complex and costly. Pharmacists play pivotal roles in thrombosis and hemostasis management and in the implementation and operation of successful multidisciplinary anticoagulation and hemostasis stewardship programs. Yet currently available residency programs do not fully prepare pharmacists for work in this dynamic and expanding field. This new ASHP-accredited PGY2 Residency in Thrombosis and Hemostasis Management will prepare pharmacists to practice in this rapidly evolving discipline and to cement the role of pharmacists in multidisciplinary anticoagulation stewardship programs.

About the Anticoagulation Forum

The Anticoagulation Forum (AC Forum) is a nonprofit organization dedicated to improving the quality of patient care by educating healthcare professionals and advocating for clinical best practices in the field of antithrombotic medications. Founded in 1991, the AC Forum is the largest organization of anticoagulation management specialists, made up of 14,000 physicians, pharmacists, and nurses representing over 3,000 anticoagulation practices and supporting over 1 million patients annually.

This program is sponsored in part by AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc.

Questions? Contact the Anticoagulation Forum at [email protected].

Updated on 2/8/2024.